AVR 48
Alternative Names: AVR-48Latest Information Update: 04 Mar 2025
At a glance
- Originator AyuVis Research
- Class Anti-infectives; Anti-inflammatories; Small molecules
- Mechanism of Action Macrophage modulators; Toll-like receptor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Adult respiratory distress syndrome; Bronchopulmonary dysplasia; Nosocomial pneumonia
Most Recent Events
- 04 Mar 2025 Preclinical trials in Adult respiratory distress syndrome in USA (IV), prior to March 2025 (AyuVis Research pipeline, March 2025)
- 04 Mar 2025 Preclinical trials in Nosocomial pneumonia in USA (IV), prior to March 2025 (AyuVis Research pipeline, March 2025)
- 04 Mar 2025 AVR 48 receives Orphan Drug status for Bronchopulmonary dysplasia (Prevention) in USA (IV), prior to March 2025 (AyuVis Research pipeline, March 2025)